en Pharmacology Pharmacology مقاله پژوهشی Original Research Article <span style="font-size:10pt"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="background:#2d7f8f"><span style="color:white">Background & Objective:</span></span></span></b><b> </b><b>&nbsp;</b><span style="font-size:9.0pt"><span style="color:black">Ovarian cancer ranks among the most prevalent gynecologic cancers in women with the majority of patients experiencing a recurrent type and developing treatment resistance. Resistance to chemotherapy drugs has been observed to trigger epithelial-mesenchymal transition (EMT), which leads to the acquisition of metastatic properties. Thus, targeting the molecular mechanism of EMT may lead to novel interventions against metastatic disease. In this research, the suppressive impacts of fucoxanthin, as a natural compound, were examined on cell migration and expression of key EMT-related markers in ovarian cancer cells which were sensitive and resistant to cisplatin. </span></span></span></span><br> <span style="font-size:10pt"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="background:#2d7f8f"><span style="color:white"><span style="letter-spacing:-.1pt">&nbsp;Materials & Methods:</span></span></span></span></b> &nbsp;<span style="font-size:9.0pt"><span style="color:black"><span style="letter-spacing:-.1pt">To determine the non-toxic concentrations of fucoxanthin for migration assay, the MTT assay was conducted. To assess the anti-migratory capacity of fucoxanthin in ovarian cancer cells which were sensitive and resistant to cisplatin, a wound-healing migration test was done in the presence of non-toxic concentrations of fucoxanthin. RT-qPCR was utilized to examine the impact of fucoxanthin on the mRNA expression of E-cadherin, vimentin and &alpha;- SMA (as EMT-related markers)</span></span></span> <span style="font-size:9.0pt"><span style="color:black"><span style="letter-spacing:-.1pt">in ovarian cancer cells.</span></span></span></span></span><br> <span style="font-size:10pt"><span new="" roman="" style="font-family:" times=""><b><span lang="EN-IN" style="font-size:9.0pt"><span style="background:#2d7f8f"><span style="color:white">Results: </span></span></span></b><b>&nbsp;</b><span style="font-size:9.0pt"><span style="color:black"><span style="letter-spacing:-.1pt">Fucoxanthin at concentrations of (1 and 2.5 &mu;M) downregulated the expression of &alpha;&ndash;SMA in cisplatin-resistant ovarian cancer cells and inhibited migration in ovarian cancer cell lines.</span></span></span></span></span><br> <span style="font-size:10pt"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:9.0pt"><span style="background:#2d7f8f"><span style="color:white">Conclusion: </span></span></span></b><span class="Char" new="" roman="" style="font-family:" times=""><span style="font-size:9.0pt">Fucoxanthin</span></span><span class="Char" new="" roman="" style="font-family:" times=""><span style="font-size:9.0pt"> exhibited remarkable efficacy in inhibiting migration in </span></span><span style="font-size:9.0pt">in ovarian cancer cells which were sensitive and resistant to cisplatin. </span><span class="Char" new="" roman="" style="font-family:" times=""><span style="font-size:9.0pt">However, more research is required to ascertain the clinical </span></span><span style="font-size:9.0pt">advantages linked to utilizing</span><span class="Char" new="" roman="" style="font-family:" times=""><span style="font-size:9.0pt"> fucoxanthin in the treatment of cisplatin-resistant ovarian cancers.</span></span><span class="Char" new="" roman="" style="font-family:" times=""><span style="font-size:14.0pt"></span></span></span></span><br> <br> &nbsp; Fucoxanthin, Ovarian cancer, EMT marker, Cell migration 135 143 http://journal.zums.ac.ir/browse.php?a_code=A-10-6860-1&slc_lang=en&sid=1 Fatemeh Mosaffa mosaffaf@mums.ac.ir 5200319475328460080420 5200319475328460080420 Yes Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran Fatemeh Valinezhad Sani valinezhadf1@mums.ac.ir 5200319475328460080421 5200319475328460080421 No Department of Laboratory Sciences, School of Paramedical and RehabilitationSciences, Mashhad University of Medical Sciences, Mashhad, Iran Shiva Ghofrani shiva.qofrani@gmail.com 5200319475328460080422 5200319475328460080422 No Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran Safa Kamalian safa_k96@yahoo.com 5200319475328460080423 5200319475328460080423 No Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran Melika Ehtesham Gharaee ehteshamm1@mums.ac.ir 5200319475328460080424 5200319475328460080424 No Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran